Ixekizumab for the Treatment of Psoriasis: A Review of Phase III Trials

INTRODUCTION: Interleukin-17 inhibitors are the newest class of monoclonal antibodies approved by the US Food and Drug Administration for the treatment of psoriasis. Preclinical and Phase II studies of ixekizumab, a high-affinity anti-IL-17A monoclonal antibody, have proved promising. METHODS: We co...

Descripción completa

Detalles Bibliográficos
Autores principales: Farahnik, Benjamin, Beroukhim, Kourosh, Zhu, Tian Hao, Abrouk, Michael, Nakamura, Mio, Singh, Rasnik, Lee, Kristina, Bhutani, Tina, Koo, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4799032/
https://www.ncbi.nlm.nih.gov/pubmed/26910853
http://dx.doi.org/10.1007/s13555-016-0102-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4799032/
https://www.ncbi.nlm.nih.gov/pubmed/26910853
http://dx.doi.org/10.1007/s13555-016-0102-0

Ejemplares similares